Stable Formulations of Linaclotide

ABSTRACT

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

CLAIM OF PRIORITY

This application is a continuation of U.S. patent application Ser. No.16/264,792 filed Feb. 1, 2019, which is the continuation of U.S. patentapplication Ser. No. 16/006,070 filed Jun. 12, 2018, which is thecontinuation of U.S. patent application Ser. No. 15/727,700 filed Oct.9, 2017, which is the continuation of U.S. patent application Ser. No.15/439,049 filed Feb. 22, 2017, which is the continuation of U.S. patentapplication Ser. No. 15/203,951 filed Jul. 7, 2016, which is thecontinuation of U.S. patent application Ser. No. 14/948,795 filed Nov.23, 2015, which is the continuation of U.S. patent application Ser. No.14/689,561 filed Apr. 17, 2015, which is the continuation of U.S. patentapplication Ser. No. 14/484,568 filed Sep. 12, 2014, which is thecontinuation of U.S. patent application Ser. No. 13/816,154 filed Feb.8, 2013, which is the United States national phase application ofPCT/US2011/047434, filed on Aug. 8, 2011. This application also claimspriority to U.S. Provisional Patent Application Ser. No. 61/372,804filed Aug. 8, 2010. The entire contents of the aforementionedapplications are incorporated herein by reference.

SEQUENCE LISTING

This application incorporates by reference in its entirety the SequenceListing entitled “IW099PCT1US1CON2_ST25.txt” which is 620 bytes in sizeand last modified on Apr. 17, 2015 and filed electronically herewith.

FIELD OF THE INVENTION

The present invention relates to stable pharmaceutical compositions oflinaclotide and methods for treating gastrointestinal disorders (e.g.,irritable bowel syndrome or chronic constipation) by administering thepharmaceutical compositions.

BACKGROUND OF THE INVENTION

Linaclotide is a peptide that is useful as an agonist of the guanylatecyclase C (GC-C) receptor in the treatment of gastrointestinaldisorders. Linaclotide is described, for example, in U.S. Pat. Nos.7,304,036 and 7,371,727, the contents of which are incorporated hereinby reference in their entirety.

There is an existing and continual need for linaclotide formulations,for example, low-dose and pediatric formulations, having improvedstability and performance. This need arises in part because of theintrinsic and chemical instability of linaclotide (for example, inducedby moisture-driven degradation reactions such as hydrolysis,deamidation, isomerization, and multimerization). These difficulties maybe exacerbated when producing pediatric formulations and other low-doseformulations of linaclotide, e.g., because the linaclotide is moredispersed and has greater surface area exposure to aqueous environmentssuch as during preparation.

The present invention provides such improved stability formulations oflinaclotide. These formulations are described herein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates stability performance data for the linaclotidecompositions prepared in Examples 2-5 as described in Example 6.

SUMMARY OF THE INVENTION

In some embodiments of the present invention, a stable pharmaceuticalcomposition is provided which comprises linaclotide, a cation or saltthereof, and a sterically hindered amine selected from meglumine,histidine or a mixture thereof, and, optionally, a polymer.

In some embodiments, the pharmaceutical composition compriseslinaclotide, a cation or pharmaceutically acceptable salt thereof and anamine selected from meglumine or a mixture of meglumine and histidine.

In some embodiments, the pharmaceutical composition compriseslinaclotide, a cation or pharmaceutically acceptable salt thereof andhistidine, wherein the composition has a molar ratio of cation:histidineof less than 2:1.

In some embodiments, a stable pharmaceutical composition is providedwhich comprises linaclotide, a cation or salt thereof, meglumine, and,optionally, a polymer.

In some embodiments, a stable pharmaceutical composition is providedwhich comprises linaclotide, a cation or salt thereof, histidine, and,optionally, a polymer.

In some embodiments, the pharmaceutical composition further comprises apolymer.

In some embodiments, a pharmaceutical composition (e.g., capsule,tablet, granule or bead) is provided which comprises linaclotide, acation or pharmaceutically acceptable salt thereof, a stericallyhindered amine selected from histidine, meglumine or a mixture thereof,and a polymer selected from polyvinyl pyrrolidone (PVP), polyvinylalcohol (PVA) or a mixture thereof.

In some embodiments, a pharmaceutical composition is provided whichcomprises linaclotide, a cation or pharmaceutically acceptable saltthereof, and melamine. In some embodiments, the pharmaceuticalcomposition further comprises a polymer.

In some embodiments, a pharmaceutical composition is provided whichcomprises linaclotide, a cation or pharmaceutically acceptable saltthereof, and gelatin. In some embodiments, the pharmaceuticalcomposition further comprises a polymer.

In some embodiments, a pharmaceutical composition is provided whichcomprises linaclotide, a cation or pharmaceutically acceptable saltthereof, and glycine. In some embodiments, the pharmaceuticalcomposition further comprises a polymer.

In some embodiments, a pharmaceutical composition is provided whichcomprises linaclotide, a cation or pharmaceutically acceptable saltthereof, and the dipeptide glycine-leucine. In some embodiments, thepharmaceutical composition further comprises a polymer.

In some embodiments, a pharmaceutical composition is provided whichcomprises linaclotide, a cation or pharmaceutically acceptable saltthereof, and the dipeptide leucine-glycine. In some embodiments, thepharmaceutical composition further comprises a polymer.

In some embodiments, a pharmaceutical composition is provided whichcomprises linaclotide, a cation or pharmaceutically acceptable saltthereof, and albumin. In some embodiments, the pharmaceuticalcomposition further comprises a polymer.

In some embodiments, a pharmaceutical composition is provided whichcomprises linaclotide, a cation or pharmaceutically acceptable saltthereof, and asparagine. In some embodiments, the pharmaceuticalcomposition further comprises a polymer.

In some embodiments, a stable low-dose pharmaceutical composition oflinaclotide is provided. In some embodiments, a stable pediatricpharmaceutical composition of linaclotide is provided.

In some embodiments, a method of treating a gastrointestinal disordercomprising administering to a patient in need thereof, a therapeuticallyeffective amount of the pharmaceutical compositions described above.

DETAILED DESCRIPTION OF THE INVENTION

Stable formulations of linaclotide (SEQ ID NO:1) are provided herein. Inaddition, methods of using the formulations to treat gastrointestinaldisorders, including irritable bowel syndrome (“IBS”) (for example,constipation-predominant IBS) and/or constipation (for example, chronicconstipation), and processes for making the compositions are provided.

It has been found that the stability of linaclotide within solid oraldosage forms (e.g., capsules and tablets) can be improved by combininglinaclotide with specific concentrations or molar ratios of a cation orpharmaceutically acceptable salt thereof, and an amine selected fromhistidine, meglumine or combination thereof. In some embodiments,stability may be improved by combining linaclotide with specificconcentrations or molar ratios of a polymer, cation or pharmaceuticallyacceptable salt thereof, and an amine selected from histidine, meglumineor combination thereof. It has been found, in some embodiments, thatcombining these components with linaclotide causes a synergisticincrease or improvement in the stability of linaclotide within thecomposition, for example as compared to similar compositions notcontaining the cation and/or sterically hindered amine and/or the sameconcentrations of these components.

The pharmaceutical composition may include any effective amount oflinaclotide. In some embodiments, for example, the composition comprisesfrom 0.001 μg to 400 μg of linaclotide. In some embodiments, forexample, the composition comprises from 0.001 μg to 350 μg oflinaclotide. In some embodiments, for example, the composition comprisesfrom 0.001 μg to 300 μg of linaclotide. In some embodiments, forexample, the composition comprises from 0.001 μg to 250 μg oflinaclotide. In some embodiments, for example, the composition comprisesfrom 0.001 μg to 200 μg of linaclotide. In some embodiments, forexample, the composition comprises from 0.001 μg to 150 μg oflinaclotide. In some embodiments, for example, the composition comprisesfrom 0.001 μg to 125 μg of linaclotide. In some embodiments, forexample, the composition comprises from 0.001 μg to 100 μg oflinaclotide. In some embodiments, for example, the composition comprisesfrom 0.001 μg to 80 μg of linaclotide. In some embodiments, for example,the composition comprises from 0.001 μg to 60 μg of linaclotide. In someembodiments, for example, the composition comprises from 0.001 μg to 50μg of linaclotide. In some embodiments, for example, the compositioncomprises from 0.001 μg to 40 μg of linaclotide. In some embodiments,for example, the composition comprises from 0.001 μg to 30 μg oflinaclotide.

In some embodiments, the composition comprises 0.001 μg to 300 μg oflinaclotide (e.g., 0.01 μg to 300 μg, 0.1 μg to 300 μg, 1 μg to 300 μg,5 μg to 300 μg, 10 μg to 300 g, 25 μg to 300 μg, or 50 μg to 300 μg oflinaclotide). In some embodiments, the composition comprises 0.001 μg to200 μg of linaclotide (e.g., 0.01 μg to 200 μg, 0.1 μg to 200 μg, 1 μgto 200 μg, 5 μg to 200 μg, 10 μg to 200 μg, 25 μg to 200 μg, or 50 μg to200 μg of linaclotide). In some embodiments, the composition comprises0.001 μg to 125 μg of linaclotide (e.g., 0.01 μg to 125 μg, 0.1 μg to125 μg, 1 μg to 125 μg, 5 μg to 125 μg, 10 μg to 125 μg, 25 μg to 125μg, or 50 μg to 125 μg of linaclotide). In some embodiments, thecomposition comprises 0.01 μg to 100 μg of linaclotide (e.g., 0.1 μg to100 μg, 1 μg to 100 μg, 5 μg to 100 μg, 10 μg to 100 μg, 25 μg to 100μg, or 50 μg to 100 μg of linaclotide). In some embodiments, thecomposition comprises 0.01 μg to 75 μg of linaclotide (e.g., 0.1 μg to75 μg, 1 μg to 75 μg, 5 μg to 75 μg, 10 μg to 75 μg, 25 μg to 75 μg, or50 μg to 75 μg of linaclotide). In some embodiments, the compositioncomprises 0.01 μg to 50 μg of linaclotide (e.g., 0.1 μg to 50 μg, 1 μgto 50 μg, 5 μg to 50 μg, 10 μg to 50 μg, or 20 μg to 50 μg oflinaclotide).

In some embodiments, the composition comprises 0.001 μg, 0.005 μg, 0.01μg, 0.05 μg, 0.1 μg, 0.15 μg, 0.25 μg, 0.5 μg, 0.75 μg, 1 μg, 2.5 μg, 5μg, 7.5 μg, 10 μg, 20 μg, 30 μg, 40 μg, 50 μg, 60 μg, 80 μg, 100 μg, 125μg, 133 μg, 150 μg, 200 μg, 250 μg, 266 μg, 300 μg, 350 μg, 400 μg, 450μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900μg, 950 μg or 1 mg of linaclotide. In some embodiments, the compositioncomprises 75 μg of linaclotide. In some embodiments, the compositioncomprises 133 μg of linaclotide. In some embodiments, the compositioncomprises 150 μg of linaclotide. In some embodiments, the compositioncomprises 266 μg of linaclotide. In some embodiments, the compositioncomprises 300 μg of linaclotide. In some embodiments, the compositioncomprises 600 μg of linaclotide.

In some embodiments, the pharmaceutical composition (e.g., bead orgranule) comprises 0.00001 to 5% by weight of linaclotide, for example,0.00001 to 3% by weight, 0.00001 to 1% by weight, 0.0001 to 0.5% byweight, 0.0001 to 0.3% by weight, 0.0001 to 0.1% by weight, 0.0001 to0.07 wt. %, 0.0005 to 0.05 wt. %, 0.005 to 0.04 wt. %, 0.008 to 0.03 wt.%, 0.008 to 0.02 wt. %, 0.008 to 0.015 wt. %, or about 0.012% by weightof linaclotide. In some embodiments, the pharmaceutical composition alsocomprises meglumine, histidine or a combination or mixture thereof. Insome embodiments, the pharmaceutical composition comprises linaclotide,a cation or pharmaceutically acceptable salt thereof and an amineselected from meglumine or a mixture of meglumine and histidine. Inother embodiments, the pharmaceutical composition comprises linaclotide,a cation or pharmaceutically acceptable salt thereof and histidine,wherein the composition has a molar ratio of cation:histidine of lessthan 2:1. For example, in some embodiments, the pharmaceuticalcomposition comprises meglumine. In some embodiments, the pharmaceuticalcomposition comprises histidine. In some embodiments, the pharmaceuticalcomposition comprises meglumine and histidine.

The pharmaceutical composition can comprise any stabilizing amount ofmeglumine, histidine or mixture thereof. In some embodiments, forexample, the composition comprises a molar ratio of meglumine, histidine(or mixture thereof) to linaclotide between 100:1 and 1:100. In someembodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 100:1 and 1:1. Insome embodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 90:1 and 2:1. Insome embodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 80:1 and 5:1. Insome embodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 70:1 and 10:1. Insome embodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 60:1 and 20:1. Insome embodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 50:1 and 30:1. Insome embodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 40:1 and 20:1. Insome embodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 100:1 and 20:1. Insome embodiments, the composition comprises a molar ratio of meglumine,histidine (or mixture thereof) to linaclotide between 100:1 and 25:1.

In some embodiments, the composition comprises a molar ratio ofmeglumine, histidine (or mixture thereof) to linaclotide between 100:1and 30:1. In some embodiments, the composition comprises a molar ratioof meglumine, histidine (or mixture thereof) to linaclotide between100:1 and 40:1. In some embodiments, the composition comprises a molarratio of meglumine, histidine (or mixture thereof) to linaclotidebetween 100:1 and 50:1. In some embodiments, the composition comprises amolar ratio of meglumine, histidine (or mixture thereof) to linaclotidebetween 100:1 and 60:1. In some embodiments, the composition comprises amolar ratio of meglumine, histidine (or mixture thereof) to linaclotidebetween 100:1 and 70:1. In some embodiments, the composition comprises amolar ratio of meglumine, histidine (or mixture thereof) to linaclotideof at least 5:1. In some embodiments, the composition comprises a molarratio of meglumine, histidine (or mixture thereof) to linaclotide of atleast 10:1. In some embodiments, the composition comprises a molar ratioof meglumine, histidine (or mixture thereof) to linaclotide of at least20:1. In some embodiments, the composition comprises a molar ratio ofmeglumine, histidine (or mixture thereof) to linaclotide of at least25:1. In some embodiments, the composition comprises a molar ratio ofmeglumine, histidine (or mixture thereof) to linaclotide of at least30:1. In some embodiments, the composition comprises a molar ratio ofmeglumine, histidine (or mixture thereof) to linaclotide of at least40:1.

In some embodiments, the pharmaceutical composition (e.g., capsule,tablet, bead or granule) comprises a molar ratio of meglumine, histidine(or mixture thereof) (e.g., an amine such as histidine or meglumine) tolinaclotide between 200:1 and 1:1. In some embodiments, the compositioncomprises a molar ratio of meglumine, histidine (or mixture thereof) tolinaclotide between 175:1 and 10:1. In some embodiments, the compositioncomprises a molar ratio of meglumine, histidine (or mixture thereof) tolinaclotide between 160:1 and 30:1. In some embodiments, the compositioncomprises a molar ratio of meglumine, histidine (or mixture thereof) tolinaclotide between 150:1 and 50:1. In some embodiments, the compositioncomprises a molar ratio of meglumine, histidine (or mixture thereof) tolinaclotide between 125:1 and 75:1. In some embodiments, the compositioncomprises a molar ratio of meglumine, histidine (or mixture thereof) tolinaclotide between 120:1 and 80:1. In some embodiments, the compositioncomprises a molar ratio of meglumine, histidine (or mixture thereof) tolinaclotide between 110:1 and 90:1.

In some embodiments, the composition (e.g., bead) comprises 0.00001 to1% by weight of histidine. In some embodiments, the compositioncomprises 0.0001 to 0.5% by weight of histidine. In some embodiments,the composition comprises 0.0001 to 0.3% by weight of histidine (forexample, 0.0001 to 0.1% by weight, 0.001 to 0.07 wt. %, 0.005 to 0.05wt. %, 0.005 to 0.04 wt. %, 0.008 to 0.03 wt. %, 0.008 to 0.02 wt. %,0.008 to 0.015 wt. %, 0.008 to 0.012 wt. %, or even about 0.01% byweight of histidine).

In some embodiments, the composition (e.g., bead or granule) comprises0.00001 to 1% by weight of meglumine. In some embodiments, thecomposition comprises 0.0001 to 0.5% by weight of meglumine. In someembodiments, the composition comprises 0.0001 to 0.3% by weight ofmeglumine (for example, 0.0001 to 0.1% by weight, 0.001 to 0.07 wt. %,0.005 to 0.05 wt. %, 0.005 to 0.04 wt. %, 0.008 to 0.03 wt. %, 0.008 to0.02 wt. %, 0.008 to 0.015 wt. %, 0.008 to 0.012 wt. %, or even about0.01% by weight of meglumine).

In some embodiments, the pharmaceutical composition comprises melamine,gelatin, glycine, glycine-leucine, albumin or asparagine in place of, orin combination with, the meglumine, histidine (or mixture thereof)component. The melamine, gelatin, glycine, glycine-leucine, albumin orasparagine can be included in the composition in any desired amount,such as at the same concentration or in the same molar ratios disclosedherein with respect to the meglumine and histidine component.

The pharmaceutical composition can comprise any suitable cation(s) orpharmaceutically acceptable salt thereof. Suitable cations include, forexample, metal or organic cations. In some embodiments, the compositioncomprises a metal cation selected from calcium, potassium, magnesium,zinc, aluminum, iron, tin, manganese, chromium, cobalt, nickel, barium,sodium, or a combination or mixture thereof. In some embodiments, thecomposition comprises a metal cation selected from calcium, potassium,magnesium, zinc, aluminum, manganese, chromium, cobalt, nickel, barium,sodium, or a combination or mixture thereof. In some embodiments, thecomposition comprises a metal cation selected from aluminum, calcium,potassium, sodium, magnesium, manganese, zinc, or a combination ormixture thereof. In some embodiments, the composition comprises a metalcation selected from calcium, magnesium, manganese, zinc, or acombination or mixture thereof. In some embodiments, the compositioncomprises a divalent metal cation. In some embodiments, the compositioncomprises a divalent metal cation selected from Ca²⁺, Mg²⁺, Zn²⁺, Mn²⁺,or a combination or mixture thereof. In some embodiments, thecomposition comprises Mg²⁺. In some embodiments, the compositioncomprises Ca^(2+.) In some embodiments, the composition comprises Zn²⁺.In some embodiments, the composition comprises aluminum.

The cation can be added to the composition in any suitable form, forexample any pharmaceutically acceptable salt with any appropriatecounterion. Suitable metal salts include, for example, calcium chloride,calcium carbonate, calcium acetate, magnesium chloride, magnesiumacetate, zinc acetate, zinc chloride, aluminum chorlide or mixturesthereof. In some embodiments, the composition comprises calciumchloride, magnesium chloride, zinc acetate, or a combination or mixturethereof. In some embodiments, the composition comprises calciumchloride. In some embodiments, the composition comprises magnesiumchloride. In some embodiments, the composition comprises zinc acetate.

Suitable organic cations include, for example, ammonium hydroxide,D-arginine, L-arginine, t-butylamine, calcium acetate hydrate, calciumcarbonate, calcium DL-malate, calcium hydroxide, choline, ethanolamine,ethylenediamine, glycine, L-histidine, L-lysine, magnesium hydroxide,N-methyl-D-glucamine, L-ornithine hydrochloride, potassium hydroxide,procaine hydrochloride, L-proline, pyridoxine, L-serine, sodiumhydroxide, DL-tryptophan, tromethamine, L-tyrosine, L-valine, carnitine,taurine, creatine malate, arginine alpha keto glutarate, omithine alphaketo glutarate, spermine acetate, spermidine chloride, or combinationsor mixtures thereof. In some embodiments, the organic cation is selectedfrom the group consisting of N-methyl D-glucamine, choline, arginine,lysine, procaine, tromethamine (TRIS), spermine, N-methyl-morpholine,glucosamine, N,N-bis 2-hydroxyethyl glycine, diazabicycloundecene,creatine, arginine ethyl ester, amantadine, rimantadine, ornithine,taurine, citrulline, or a combination or mixture thereof.

The pharmaceutical composition can comprise any stabilizing amount of acation. In some embodiments, the pharmaceutical composition comprises amolar ratio of cation (e.g., Ca²⁺ or a salt thereof) to linaclotidebetween 200:1 and 1:1. In some embodiments, the composition comprises amolar ratio of cation (e.g., Ca²⁺ or a salt thereof) to linaclotidebetween 175:1 and 10:1. In some embodiments, the composition comprises amolar ratio of cation (e.g., Ca²⁺ or a salt thereof) to linaclotidebetween 160:1 and 30:1. In some embodiments, the composition comprises amolar ratio of cation (e.g., Ca²⁺ or a salt thereof) to linaclotidebetween 150:1 and 50:1. In some embodiments, the composition comprises amolar ratio of cation (e.g., Ca²⁺ or a salt thereof) to linaclotidebetween 125:1 and 75:1. In some embodiments, the composition comprises amolar ratio of cation (e.g., Ca²⁺ or a salt thereof) to linaclotidebetween 120:1 and 80:1. In some embodiments, the composition comprises amolar ratio of cation (e.g., Ca²⁺ or a salt thereof) to linaclotidebetween 110:1 and 90:1.

In some embodiments, the composition (e.g., bead or granule) comprises0.0001 to 2% by weight of Ca²⁺ or a pharmaceutically acceptable saltthereof. In some embodiments, the composition comprises 0.0005 to 1.5wt. % of Ca²⁺ or a salt thereof. In some embodiments, the compositioncomprises 0.001 to 1 wt. % (e.g., 0.01 to 0.75 wt. %, 0.05 to 0.5 wt. %,0.05 to 0.3 wt. %, 0.05 to 0.2 wt. %, 0.07 to 0.15 wt. %, or even about0.1% by weight) of Ca²⁺ or a salt thereof.

In some embodiments, the pharmaceutical composition comprises a molarratio of cation to linaclotide between 100:1 and 1:100. In someembodiments, the composition comprises a molar ratio of cation tolinaclotide between 100:1 and 1:1. In some embodiments, the compositioncomprises a molar ratio of cation to linaclotide between 90:1 and 2:1.In some embodiments, the composition comprises a molar ratio of cationto linaclotide between 80:1 and 5:1. In some embodiments, thecomposition comprises a molar ratio of cation to linaclotide between70:1 and 10:1. In some embodiments, the composition comprises a molarratio of cation to linaclotide between 60:1 and 20:1. In someembodiments, the composition comprises a molar ratio of cation tolinaclotide between 50:1 and 30:1. In some embodiments, the compositioncomprises a molar ratio of cation to linaclotide between 40:1 and 20:1.In some embodiments, the composition comprises a molar ratio of cationto linaclotide between 100:1 and 20:1. In some embodiments, thecomposition comprises a molar ratio of cation to linaclotide between100:1 and 25:1. In some embodiments, the composition comprises a molarratio of cation to linaclotide between 100:1 and 30:1. In someembodiments, the composition comprises a molar ratio of cation tolinaclotide between 100:1 and 40:1. In some embodiments, the compositioncomprises a molar ratio of cation to linaclotide between 100:1 and 50:1.In some embodiments, the composition comprises a molar ratio of cationto linaclotide between 100:1 and 60:1. In some embodiments, thecomposition comprises a molar ratio of cation to linaclotide between100:1 and 70:1. In some embodiments, the composition comprises a molarratio of cation to linaclotide of at least 5:1. In some embodiments, thecomposition comprises a molar ratio of cation to linaclotide of at least10:1. In some embodiments, the composition comprises a molar ratio ofcation to linaclotide of at least 20:1. In some embodiments, thecomposition comprises a molar ratio of cation to linaclotide of at least25:1. In some embodiments, the composition comprises a molar ratio ofcation to linaclotide of at least 30:1. In some embodiments, thecomposition comprises a molar ratio of cation to linaclotide of at least40:1. In some embodiments, the composition comprises a molar ratio ofcation to linaclotide of at least 60:1.

The pharmaceutical composition can comprise any suitable polymer.Suitable polymers include, for example, polyvinyl pyrrolidone (PVP),polyvinyl alcohol (PVA), hydroxylpropyl methyl cellulose (HPMC),hydroxylpropyl cellulose (HPC), methyl cellulose, methacrylate polymers,cyclodextrin, dextrin, dextran, polyacrylic acid, chitosan, guar gum,xanthan gum, polyethylene oxide (e.g., polyethylene polypropyleneoxide), poly (sodium vinylsulfonate), polyethylene glycol,poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate,a poloxamer (e.g., Pluronic® products available from BASF), alginate,trehalose, sucrose, inulin, or a combination or mixture thereof. In someembodiments, the composition comprises a polymer selected from PVP, PVA,methacrylate polymers, cyclodextrin, dextran, polyacrylic acid,chitosan, guar gum, xanthan gum, polyethylene oxide, polyethyleneglycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinylacetate, a poloxamer, or a combination or mixture thereof. In someembodiments, the composition comprises PVP, PVA, polyethylene oxide, ora mixture thereof. In some embodiments, the composition comprises PVP,PVA, or a mixture thereof. In some embodiments, the compositioncomprises PVP. In some embodiments, the composition comprises PVA.

The composition can contain any suitable amount of a polymer. In someembodiments, the composition (e.g., bead or granule) comprises 0.1 to10% by weight of a polymer (for example, PVA or PVP). In someembodiments, the composition comprises 1 to 5 wt. % of a polymercomponent. In some embodiments, the composition comprises 2 to 5 wt. %(e.g., 3 to 5 wt. %, 3.5 to 4.5 wt. %, or about 4% by weight) of apolymer (e.g., PVA or PVP).

In some embodiments, the pharmaceutical composition comprises PVP and astabilizing amount of an amino acid selected from meglumine, histidineor a mixture thereof. In some embodiments, the composition comprises PVPand a stabilizing amount of histidine. In some embodiments, thecomposition comprises PVP and a stabilizing amount of meglumine.

In some embodiments, the pharmaceutical composition comprises PVA and anamino acid selected from meglumine, histidine or a mixture thereof. Insome embodiments, the composition comprises PVA and histidine. In someembodiments, the composition comprises PVA and meglumine.

In some embodiments, the pharmaceutical composition comprises astabilizing amount of an amino acid selected from histidine, meglumineand combinations thereof; and a stabilizing amount of a cation (e.g., ametal cation, for example, a divalent metal cation selected from Mg²⁺,Ca²⁺, Zn²⁺ or a salt thereof or a combination or mixture thereof). Insome embodiments, the composition comprises a stabilizing amount of anamino acid selected from histidine, meglumine and combinations thereof;and a stabilizing amount of a divalent metal cation selected from Mg²⁺,Ca²⁺ or a salt thereof or a combination or mixture thereof. In someembodiments, the composition comprises a stabilizing amount ofhistidine, meglumine or a mixture thereof; and a divalent metal cationselected from Ca²⁺, Zn²⁺ or a salt thereof or a combination or mixturethereof. In some embodiments, the composition comprises a stabilizingamount of meglumine and a stabilizing amount of Ca²⁺ or a salt thereof.In some embodiments, the composition comprises a stabilizing amount ofhistidine and a stabilizing amount of Ca²⁺ or a salt thereof. In someembodiments, the composition comprises a cation and amino acid (e.g.,meglumine, histidine or mixture thereof) in a molar ratio ofcation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine) between 2:1and 1:2. In some embodiments, the composition comprises a cation andamino acid (e.g., meglumine, histidine or mixture thereof) in a molarratio of cation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine)between 1.75:1 and 1:1.75. In some embodiments, the compositioncomprises a cation and amino acid (e.g., meglumine, histidine or mixturethereof) in a molar ratio of cation:amino acid (e.g., Ca²⁺:meglumine orCa²⁺:histidine) between 1.5:1 and 1:1.5. In some embodiments, thecomposition comprises a cation and amino acid (e.g., meglumine,histidine or mixture thereof) in a molar ratio of cation:amino acid(e.g., Ca²⁺:meglumine or Ca²⁺:histidine) between 1.25:1 and 1:1.25. Insome embodiments, the composition comprises a cation and amino acid(e.g., meglumine, histidine or mixture thereof) in a molar ratio ofcation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine) between 1.1:1and 1:1.1.

In some embodiments, the composition comprises a cation and amino acid(e.g., meglumine, histidine or mixture thereof) in a molar ratio ofcation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine) of less than5:1. In some embodiments, the composition comprises a cation and aminoacid (e.g., meglumine, histidine or mixture thereof) in a molar ratio ofcation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine) of less than4:1. In some embodiments, the composition comprises a cation and aminoacid (e.g., meglumine, histidine or mixture thereof) in a molar ratio ofcation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine) of less than3:1. In some embodiments, the composition comprises a cation and aminoacid (e.g., meglumine, histidine or mixture thereof) in a molar ratio ofcation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine) of less than2:1. In some embodiments, the composition comprises a cation and aminoacid (e.g., meglumine, histidine or mixture thereof) in a molar ratio ofcation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine) of less than1.75:1. In some embodiments, the composition comprises a cation andamino acid (e.g., meglumine, histidine or mixture thereof) in a molarratio of cation:amino acid (e.g., Ca²⁺:meglumine or Ca²⁺:histidine) ofless than 1.5:1. In some embodiments, the composition comprises a cationand amino acid (e.g., meglumine, histidine or mixture thereof) in amolar ratio of cation:amino acid (e.g., Ca²⁺:meglumine orCa²⁺:histidine) of less than 1.25:1.

In some preferred embodiments, the composition comprises a cation (e.g.,Ca²⁺) and an amino acid selected from meglumine, histidine or mixturethereof in a molar ratio of cation:amino acid (e.g., Ca²⁺:meglumine orCa²⁺:histidine) between about 1.5:1 and 0.5:1. In some preferredembodiments, the composition comprises a cation (e.g., Ca²⁺) and anamino acid selected from meglumine, histidine or mixture thereof in amolar ratio of cation:amino acid (e.g., Ca²⁺:meglumine orCa²⁺:histidine) between about 1.4:1 and 0.6:1. In some preferredembodiments, the composition comprises a cation (e.g., Ca²⁺) and anamino acid selected from meglumine, histidine or mixture thereof in amolar ratio of cation:amino acid (e.g., Ca²⁺:meglumine orCa²⁺:histidine) between about 1.3:1 and 0.7:1. In some preferredembodiments, the composition comprises a cation (e.g., Ca²⁴) and anamino acid selected from meglumine, histidine or mixture thereof in amolar ratio of cation:amino acid (e.g., Ca²⁺:meglumine orCa²⁺:histidine) between about 1.2:1 and 0.8:1. In some preferredembodiments, the composition comprises a cation (e.g., Ca²⁺) and anamino acid selected from meglumine, histidine or mixture thereof in amolar ratio of cation:amino acid (e.g., Ca²⁺:meglumine orCa²⁺:histidine) between about 1.1:1 and 0.9:1.

In some embodiments, the pharmaceutical composition comprises (i) apolymer (e.g., PVP or PVA), (ii) a stabilizing amount of meglumine,histidine or a combination thereof, and (iii) a stabilizing amount of acation (e.g., a divalent metal cation for example Mg²⁺, Ca²⁺, Zn²⁺ or apharmaceutically-acceptable salt thereof or a combination or mixturethereof). In some embodiments, the pharmaceutical composition comprises(i) a polymer (e.g., PVP and/or PVA), (ii) histidine or meglumine, and(iii) Mg²⁺, Ca²⁺, Zn²⁺ or a salt thereof or a combination or mixturethereof. In some embodiments, the composition comprises a stabilizingamount of PVA and stabilizing amounts of meglumine, and a metal cation.

In some embodiments, the pharmaceutical composition (e.g., bead orgranule) comprises linaclotide (e.g., a therapeutically effective amountof linaclotide, for example, between 0.01±g and 300 μg, between 0.01 μgand 150 μg, or between 0.01 μg and 125 gig of linaclotide), histidine ina molar ratio to linaclotide between 150:1 and 50:1 (e.g., between 125:1and 75:1, between 120:1 and 80:1, between 110:1 and 90:1 or a molarratio of histidine to linaclotide of about 100:1), Ca²⁺ or a saltthereof in a molar ratio to linaclotide between 150:1 and 50:1 (e.g.,between 125:1 and 75:1, between 120:1 and 80:1, between 110:1 and 90:1or a molar ratio of Ca²⁺ or a salt thereof to linaclotide of about100:1) and optionally a polymer (e.g., PVA or PVP).

In some embodiments, the pharmaceutical composition (e.g., bead orgranule) comprises linaclotide (e.g., a therapeutically effective amountof linaclotide, for example, between 0.01 μg and 300 μg, between 0.01 μgand 150 μg, or between 0.01 μg and 125 μg of linaclotide), meglumine ina molar ratio to linaclotide between 150:1 and 50:1 (e.g., between 125:1and 75:1, between 120:1 and 80:1, between 110:1 and 90:1 or even a molarratio of meglumine to linaclotide of about 100:1), Ca²⁺ or a saltthereof in a molar ratio to linaclotide between 150:1 and 50:1 (e.g.,between 125:1 and 75:1, between 120:1 and 80:1, between 110:1 and 90:1or a molar ratio of Ca²⁺ or a salt thereof to linaclotide of about100:1) and optionally a polymer (e.g., PVA or PVP).

In some embodiments, the composition (e.g., bead or granule) compriseslinaclotide (e.g., a therapeutically effective amount of linaclotide,for example, between 0.01 μg and 300 μg, between 0.01 μg and 150 μg, orbetween 0.01 μg and 125 μg of linaclotide), an amino acid (e.g.,meglumine or histidine) in a concentration of 0.005 to 0.05% by weight(e.g., 0.005 to 0.04 wt. %, 0.008 to 0.03 wt. %, 0.008 to 0.02 wt. %,0.008 to 0.015 wt. %, 0.008 to 0.012 wt. %, or even about 0.01 wt. %), ametal cation (e.g., Ca²⁺ or a salt thereof) in a concentration of 0.01to 0.75% by weight (e.g., 0.05 to 0.5 wt. %, 0.05 to 0.3 wt. %, 0.05 to0.2 wt. %, 0.07 to 0.15 wt. %, or even about 0.1% by weight) andoptionally a polymer (e.g., PVA or PVP).

In some embodiments, the composition (e.g., bead or granule) compriseslinaclotide (e.g., a therapeutically effective amount of linaclotide,for example, between 0.01 μg and 300 μg, between 0.01 μg and 150 μg, orbetween 0.01 μg and 125 μg of linaclotide), meglumine in a concentrationof 0.005 to 0.05% by weight (e.g., 0.005 to 0.04 wt. %, 0.008 to 0.03wt. %, 0.008 to 0.02 wt. %, 0.008 to 0.015 wt. %, 0.008 to 0.012 wt. %,or even about 0.01 wt. %), Ca²⁺ or a salt thereof in a concentration of0.01 to 0.75% by weight (e.g., 0.05 to 0.5 wt. %, 0.05 to 0.3 wt. %,0.05 to 0.2 wt. %, 0.07 to 0.15 wt. %, or even about 0.1% by weight) andoptionally a polymer (e.g., PVA or PVP).

In some embodiments, the composition (e.g., bead or granule) compriseslinaclotide (e.g., a therapeutically effective amount of linaclotide,for example, between 0.01 μg and 300 μg, between 0.01 μg and 150 μg, orbetween 0.01 μg and 125 μg of linaclotide), histidine in a concentrationof 0.005 to 0.05% by weight (e.g., 0.005 to 0.04 wt. %, 0.008 to 0.03wt. %, 0.008 to 0.02 wt. %, 0.008 to 0.015 wt. %, 0.008 to 0.012 wt. %,or even about 0.01 wt. %), Ca²⁺ or a salt thereof in a concentration of0.01 to 0.75% by weight (e.g., 0.05 to 0.5 wt. %, 0.05 to 0.3 wt. %,0.05 to 0.2 wt. %, 0.07 to 0.15 wt. %, or even about 0.1% by weight) andoptionally a polymer (e.g., PVA or PVP).

The pharmaceutical composition may also comprise any one or more fillingagents. Suitable filling agents include, but are not limited to, starch,calcium carbonate, calcium sulfate, hydroxylpropylmethyl cellulose,fructose, methyl cellulose, dextrates, dextrose, dextran, lactitol,maltose, sucrose, sorbitol, isomalt, pregelatinized starch, dicalciumphosphate, microcrystalline cellulose, mannitol, gelatin, trehalose,erythitol, maltitol, lactose, glucose, or a combination thereof, or amixture thereof. In some embodiments, the filling agent is isomalt. Insome embodiments, the filling agent is gelatin. In some embodiments, thefilling agent is mannitol. In some embodiments, the filling agent ispregelatinized starch. In some embodiments, the filling agent ismicrocrystalline cellulose.

The pharmaceutical composition can comprise any suitable concentrationof filling agent. In some embodiments, for example, the compositioncomprises one or more filling agents in a concentration of 0.1-99% byweight, relative to the total weight of the composition. In someembodiments, for example, the composition comprises one or more fillingagents in a concentration of 1-95 wt. % of filling agent(s), relative tothe total weight of the composition. In some embodiments, for example,the composition comprises one or more filling agents in a concentrationof 10-90 wt. % of filling agent(s), relative to the total weight of thecomposition. In some embodiments, for example, the composition comprisesone or more filling agents in a concentration of 20-90 wt. % of fillingagent(s), relative to the total weight of the composition. In someembodiments, for example, the composition comprises one or more fillingagents in a concentration of 25-85 wt. % of filling agent(s), relativeto the total weight of the composition. In some embodiments, forexample, the composition comprises one or more filling agents in aconcentration of 30-80 wt. % of filling agent(s), relative to the totalweight of the composition. In some embodiments, for example, thecomposition comprises one or more filling agents in a concentration of40-70 wt. % of filling agent(s), relative to the total weight of thecomposition. In some embodiments, for example, the composition comprisesone or more filling agents in a concentration of 10-60 wt. % of fillingagent(s), relative to the total weight of the composition. In someembodiments, for example, the composition comprises one or more fillingagents in a concentration of 20-50 wt. % of filling agent(s), relativeto the total weight of the composition. In some embodiments, thecomposition comprises one or more filling agents in a concentration ofat least 20 wt. %, for example, at least 40 wt. %, at least 60 wt. %, atleast 70 wt. %, at least 80 wt. %, or at least 90 wt. %, relative to thetotal weight of the composition.

In some embodiments, the pharmaceutical composition (e.g., orallydisintegrating composition) can comprise one or more plasticizers.Suitable plasticizers include, but are not limited to, polyethyleneglycol, propylene glycol, glycerin, glycerol, monoacetin, diacetin,triacetin, dimethyl phthalate, diethyl phthalate, dibutyl phthalate,dibutyl sebacate, triethyl titrate, tributyl citrate, triethyl citrate,triethyl acetyl citrate, castor oil, acetylated monoglycerides, sorbitolor combinations thereof. In exemplary embodiments, the concentration ofthe plasticizer in the formulation may be about 0 to about 30 wt %, forexample, about 1 to about 20 wt %, about 0.1 to about 10 wt %, about 1to about 5 wt %, or even 0.1 to about 4 wt %.

In some embodiments, the pharmaceutical composition is anorally-disintegrating composition and comprises a film-forming agent, awater-soluble polymer, a combination of two or more water-solublepolymers or a combination of a water-soluble polymer and awater-insoluble or poorly-soluble polymer. Water-soluble polymers thatmay be used in the orally-dissolving formulations of the presentinvention include, but are not limited to, cellulose derivatives,synthetic polymers polyacrylates and natural gums. For example, thewater-soluble polymers used in the orally-dissolving formulations of thepresent invention may include, but are not limited to, methyl cellulose,hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose,hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate butyrate,amylose, dextran, casein, pullulan, gelatin, pectin, agar, carrageenan,xanthan gum, tragacanth, guar gum, acacia gum, arabic gum, polyethyleneglycol, polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol,cyclodextrin, carboxyvinyl polymers, sodium alginate, polyacrylic acid,methylmethacrylate or mixtures thereof. In exemplary embodiments, theconcentration of the water-soluble polymer in the formulation may beabout 20% to about 90% (by weight), preferably between about 40% toabout 80% (by weight).

One skilled in the art, with the benefit of this disclosure, willunderstand that other components may be included to enhance one or moreproperties of the pharmaceutical compositions. In some embodiments, forexample, the pharmaceutical composition may include one or moredisintegrants, lubricants, anti-caking additives, anti-microbial agents,antifoaming agents, emulsifiers, surfactants, buffering agents, and/orcoloring agents.

Suitable disintegrants include, for example, agar-agar, calciumcarbonate, microcrystalline cellulose, croscarmellose sodium,crospovidone, povidone, polacrilin potassium, sodium starch glycolate,potato or tapioca starch, other starches, pre-gelatinized starch, clays,other algins, other celluloses, gums, and mixtures thereof. In someembodiments, the disintegrant is crospovidone. In some embodiments, thedisintegrant is croscarmellose sodium.

Suitable lubricants include, for example, calcium stearate, magnesiumstearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol,polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate,talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil,sunflower oil, sesame oil, olive oil, corn oil and soybean oil), zincstearate, ethyl oleate, ethyl laurate, agar, syloid silica gel (AEROSIL200, W.R. Grace Co., Baltimore, Md. USA), a coagulated aerosol ofsynthetic silica (Evonik Degussa Co., Plano, Tex. USA), a pyrogenicsilicon dioxide (CAB-O-SIL, Cabot Co., Boston, Mass. USA), and mixturesthereof.

Suitable anti-caking additives include, for example, calcium silicate,magnesium silicate, silicon dioxide, colloidal silicon dioxide, talc,and mixtures thereof. In some embodiments, the composition comprisesabout 0.01 wt. % to about 5 wt. % of an anti-caking additive (e.g.,talc). In some embodiments, the composition comprises about 0.05 wt. %to about 2 wt. % of an anti-caking additive (e.g., talc). In someembodiments, the composition comprises about 0.1 wt. % to about 1 wt. %of an anti-caking additive (e.g., talc). In some embodiments, thecomposition comprises about 0.25 wt. % to about 0.75 wt. % (e.g., about0.5 wt. %) of an anti-caking additive (e.g., talc).

Suitable anti-microbial additives that may be used, e.g., as apreservative for the linaclotide compositions, include, for example,benzalkonium chloride, benzethonium chloride, benzoic acid, benzylalcohol, butyl paraben, cetylpyridinium chloride, cresol, chlorobutanol,dehydroacetic acid, ethylparaben, methylparaben, phenol, phenylethylalcohol, phenoxyethanol, phenylmercuric acetate, phenylmercuric nitrate,potassium sorbate, propylparaben, sodium benzoate, sodiumdehydroacetate, sodium propionate, sorbic acid, thimersol, thymo, andmixtures thereof.

In some embodiments, the pharmaceutical composition (e.g.,orally-disintegrating composition) may comprise a taste-masking agent.Generally, any natural or synthetic flavoring agent or sweetening agentknown in the art may be used in the pharmaceutical compositions of thepresent invention. For example, suitable taste-masking agents include,but are not limited to, essential oils, water-soluble extracts, sugar,monosaccharides, oligosaccharides, aldose, ketose, dextrose, maltose,lactose, glucose, fructose, sucrose, mannitol xylitol, D-sorbitol,erythritol, pentitol, hexitol, malitol, acesulfame potassium, talin,glycyrrhizin, sucralose, aspartame, saccharin, sodium saccharin, sodiumcyclamate, eugenyl formate aldehyde flavorings and combinations thereof.

Exemplary aldehyde flavorings that may be used include, but are notlimited to acetaldehyde (apple); benzaldehyde (cherry, almond); cinnamicaldehyde (cinnamon); citral, i.e., alpha citral (lemon, lime); neral,i.e., beta citral (lemon, lime); decanal (orange, lemon); ethyl vanillin(vanilla, cream); heliotropine, i.e., piperonal (vanilla, cream);vanillin (vanilla, cream); alpha-amyl cinnamaldehyde (spicy fruityflavors); butyraldehyde (butter, cheese); valeraldehyde (butter,cheese); citronellal (modifies, many types); decanal (citrus fruits);aldehyde C-8 (citrus fruits); aldehyde C-9 (citrus fruits); aldehydeC-12 (citrus fruits); 2-ethyl butyraldehyde (berry fruits); hexenal,i.e., trans-2 (berry fruits); tolyl aldehyde (cherry, almond);veratraldehyde (vanilla); 2,6-dimethyl-5-heptenal, i.e., melonal(melon); 2-6-dimethyloctanal (green fruit); and 2-dodecenal (citrus,mandarin). In some embodiments, the taste-masking agents may includecombination of acesulfame potassium and flavors. One skilled in the artwith the benefit of the present disclosure will appreciate that otherand further ingredients may be included in the pharmaceuticalcomposition of the present invention, for example, a matrix-formingpolymer permeation enhancer, substance for imparting mucoadhesiveproperties, or other auxiliary substances.

The composition may also comprise any suitable pharmaceuticallyacceptable carrier or medium. Suitable pharmaceutically acceptablecarriers include, for example, any solvents, dispersants, pH-bufferingagents, coatings, absorption-promoting agents, controlled-releaseagents, and one or more inert excipients (e.g., filling agents,starches, polyols, granulating agents, microcrystalline cellulose,diluents, lubricants, binders, disintegrating agents), or the like. Inaddition, the compositions can contain any desired additionalcomponents, additives, and/or species, for example, surface activeadditives, dispersing additives, humectants, suspending agents,solubilizers, buffering agents, disintegrants, preservatives, colorants,flavorants, and the like. In some embodiments, the composition comprisesone or more ion species that interact with linaclotide.

The composition can also comprise any suitable pH buffering agent. Insome embodiments, the pH buffering agent is present in the compositionin an amount sufficient to achieve the isoelectric point of linaclotide.In the regard, the composition can have any desired pH. In someembodiments, the composition has a pH of 2 to 5 (for example, a pH of 2to 4.5, a pH of 2 4o 4, a pH of 2.5 to 4, a pH of 2.5 to 3.5, a pH of2.5 to 3, or even a pH of 3).

In some embodiments, the composition comprises linaclotide and ahydrolysis product, e.g., a hydrolysis product comprising or having astructure of:

The composition can contain any desired concentration of the hydrolysisproduct. In some embodiments, the composition comprises less than 10 wt.% of the hydrolysis product. In some embodiments, the compositioncomprises less than 7 wt. % of the hydrolysis product. In someembodiments, the composition comprises less than 6 wt. % of thehydrolysis product. In some embodiments, the composition comprises lessthan 5 wt. % of the hydrolysis product. In some embodiments, thecomposition comprises less than 4 wt. % of the hydrolysis product. Insome embodiments, the composition comprises less than 3 wt. % of thehydrolysis product. In some embodiments, the composition comprises lessthan 2 wt. % of the hydrolysis product. In some embodiments, thecomposition comprises less than 1 wt. % of the hydrolysis product. Insome embodiments, the composition comprises between 0.01 and 10 wt. % ofthe hydrolysis product. In some embodiments, the composition comprisesbetween 0.1 and 7 wt. % of the hydrolysis product. In some embodiments,the composition comprises between 0.1 and 5 wt. % of the hydrolysisproduct. In some embodiments, the composition comprises between 0.5 and5 wt. % of the hydrolysis product. In some embodiments, the compositioncomprises between 1 and 5 wt. % of the hydrolysis product. In someembodiments, the composition comprises between 0.1 and 4 wt. % of thehydrolysis product. In some embodiments, the composition comprisesbetween 0.5 and 4 wt. % of the hydrolysis product. In some embodiments,the composition comprises between 1 and 4 wt. % of the hydrolysisproduct. In some embodiments, the composition comprises between 0.1 and3 wt. % of the hydrolysis product. In some embodiments, the compositioncomprises between 0.5 and 3 wt. % of the hydrolysis product. In someembodiments, the composition comprises between 1 and 3 wt. % of thehydrolysis product. In some embodiments, the composition comprisesbetween 0.1 and 2.5 wt. % of the hydrolysis product. In someembodiments, the composition comprises between 0.5 and 2.5 wt. % of thehydrolysis product. In some embodiments, the composition comprisesbetween 1 and 2.5 wt. % of the hydrolysis product. In some embodiments,the composition comprises between 0.1 and 2 wt. % of the hydrolysisproduct. In some embodiments, the composition comprises between 0.5 and2 wt. % of the hydrolysis product. In some embodiments, the compositioncomprises between 1 and 2 wt. % of the hydrolysis product. In someembodiments, the composition comprises between 0.1 and 1.5 wt. % of thehydrolysis product. In some embodiments, the composition comprisesbetween 0.5 and 1.5 wt. % of the hydrolysis product. In someembodiments, the composition comprises between 0.1 and 1 wt. % of thehydrolysis product. In some embodiments, the composition comprisesbetween 0.5 and 1 wt. % of the hydrolysis product.

In some embodiments, the composition comprises linaclotide and aformaldehyde imine product, e.g., a formaldehyde imine productcomprising or having a structure of:

The composition can contain any desired concentration of theformaldehyde imine product. In some embodiments, the compositioncomprises less than 10 wt. % of the formaldehyde imine product. In someembodiments, the composition comprises less than 7 wt. % of theformaldehyde imine product. In some embodiments, the compositioncomprises less than 6 wt. % of the formaldehyde imine product. In someembodiments, the composition comprises less than 5 wt. % of theformaldehyde imine product. In some embodiments, the compositioncomprises less than 4 wt. % of the formaldehyde imine product. In someembodiments, the composition comprises less than 3 wt. % of theformaldehyde imine product. In some embodiments, the compositioncomprises less than 2 wt. % of the formaldehyde imine product. In someembodiments, the composition comprises less than 1 wt. % of theformaldehyde imine product. In some embodiments, the compositioncomprises between 0.01 and 10 wt. % of the formaldehyde imine product.In some embodiments, the composition comprises between 0.1 and 7 wt. %of the formaldehyde imine product. In some embodiments, the compositioncomprises between 0.1 and 5 wt. % of the formaldehyde imine product. Insome embodiments, the composition comprises between 0.5 and 5 wt. % ofthe formaldehyde imine product. In some embodiments, the compositioncomprises between 1 and 5 wt. % of the formaldehyde imine product. Insome embodiments, the composition comprises between 0.1 and 4 wt. % ofthe formaldehyde imine product. In some embodiments, the compositioncomprises between 0.5 and 4 wt. % of the formaldehyde imine product. Insome embodiments, the composition comprises between 1 and 4 wt. % of theformaldehyde imine product. In some embodiments, the compositioncomprises between 0.1 and 3 wt. % of the formaldehyde imine product. Insome embodiments, the composition comprises between 0.5 and 3 wt. % ofthe formaldehyde imine product. In some embodiments, the compositioncomprises between 1 and 3 wt. % of the formaldehyde imine product. Insome embodiments, the composition comprises between 0.1 and 2.5 wt. % ofthe formaldehyde imine product. In some embodiments, the compositioncomprises between 0.5 and 2.5 wt. % of the formaldehyde imine product.In some embodiments, the composition comprises between 1 and 2.5 wt. %of the formaldehyde imine product. In some embodiments, the compositioncomprises between 0.1 and 2 wt. % of the formaldehyde imine product. Insome embodiments, the composition comprises between 0.5 and 2 wt. % ofthe formaldehyde imine product. In some embodiments, the compositioncomprises between 1 and 2 wt. % of the formaldehyde imine product. Insome embodiments, the composition comprises between 0.1 and 1.5 wt. % ofthe formaldehyde imine product. In some embodiments, the compositioncomprises between 0.5 and 1.5 wt. % of the formaldehyde imine product.In some embodiments, the composition comprises between 0.1 and 1 wt. %of the formaldehyde imine product. In some embodiments, the compositioncomprises between 0.5 and 1 wt. % of the formaldehyde imine product.

In some embodiments, the composition comprises linaclotide and a peptidemodified with the addition of methylene at the α-amine group of theN-terminal Cys₁ that is cross-linked to the amine group of Cys₂ to forman imidazolidinone 5 membered ring at the N-terminus of the peptide(“Cys₁-IMD product”) comprising or having a structure of:

The composition can contain any desired concentration of the Cys₁-IMDproduct. In some embodiments, the composition comprises less than 10 wt.% of the Cys₁-IMD product. In some embodiments, the compositioncomprises less than 7 wt. % of the Cys₁-IMD product. In someembodiments, the composition comprises less than 6 wt. % of the Cys₁-IMDproduct. In some embodiments, the composition comprises less than 5 wt.% of the Cys₁-IMD product. In some embodiments, the compositioncomprises less than 4 wt. % of the Cys₁-IMD product. In someembodiments, the composition comprises less than 3 wt. % of the Cys₁-IMDproduct. In some embodiments, the composition comprises less than 2 wt.% of the Cys₁-IMD product. In some embodiments, the compositioncomprises less than 1 wt. % of the Cys₁-IMD product. In someembodiments, the composition comprises between 0.01 and 10 wt. % of theCys₁-IMD product. In some embodiments, the composition comprises between0.1 and 7 wt. % of the Cys₁-IMD product. In some embodiments, thecomposition comprises between 0.1 and 5 wt. % of the Cys₁-IMD product.In some embodiments, the composition comprises between 0.5 and 5 wt. %of the Cys₁-IMD product. In some embodiments, the composition comprisesbetween 1 and 5 wt. % of the Cys₁-IMD product. In some embodiments, thecomposition comprises between 0.1 and 4 wt. % of the Cys₁-IMD product.In some embodiments, the composition comprises between 0.5 and 4 wt. %of the Cys₁-IMD product. In some embodiments, the composition comprisesbetween 1 and 4 wt. % of the Cys₁-IMD product. In some embodiments, thecomposition comprises between 0.1 and 3 wt. % of the Cyst-IMD product.In some embodiments, the composition comprises between 0.5 and 3 wt. %of the Cys₁-IMD product. In some embodiments, the composition comprisesbetween 1 and 3 wt. % of the Cys₁-IMD product. In some embodiments, thecomposition comprises between 0.1 and 2.5 wt. % of the Cys₁-IMD product.In some embodiments, the composition comprises between 0.5 and 2.5 wt. %of the Cys₁-IMD product. In some embodiments, the composition comprisesbetween 1 and 2.5 wt. % of the Cys₁-IMD product. In some embodiments,the composition comprises between 0.1 and 2 wt. % of the Cys₁-IMDproduct. In some embodiments, the composition comprises between 0.5 and2 wt. % of the Cys₁-IMD product. In some embodiments, the compositioncomprises between 1 and 2 wt. % of the Cys₁-IMD product. In someembodiments, the composition comprises between 0.1 and 1.5 wt. % of theCyst-IMD product. In some embodiments, the composition comprises between0.5 and 1.5 wt. % of the Cys₁-IMD product. In some embodiments, thecomposition comprises between 0.1 and 1 wt. % of the Cys₁-IMD product.In some embodiments, the composition comprises between 0.5 and 1 wt. %of the Cys₁-IMD product.

In some embodiments, the composition comprises linaclotide and anoxidation product, e.g., an oxidation product comprising or having astructure of:

Alternatively, or in addition, the composition comprises linaclotide andan oxidation product having the depicted structure but wherein oxidationoccurs at any one or more of the six depicted cysteinyl sulfurs. Thecomposition can contain any desired concentration of the oxidationproduct. In some embodiments, the composition comprises less than 10 wt.% of the oxidation product. In some embodiments, the compositioncomprises less than 7 wt. % of the oxidation product. In someembodiments, the composition comprises less than 6 wt. % of theoxidation product. In some embodiments, the composition comprises lessthan 5 wt. % of the oxidation product. In some embodiments, thecomposition comprises less than 4 wt. % of the oxidation product. Insome embodiments, the composition comprises less than 3 wt. % of theoxidation product. In some embodiments, the composition comprises lessthan 2 wt. % of the oxidation product. In some embodiments, thecomposition comprises less than 1 wt. % of the oxidation product. Insome embodiments, the composition comprises between 0.01 and 10 wt. % ofthe oxidation product. In some embodiments, the composition comprisesbetween 0.1 and 7 wt. % of the oxidation product. In some embodiments,the composition comprises between 0.1 and 5 wt. % of the oxidationproduct. In some embodiments, the composition comprises between 0.5 and5 wt. % of the oxidation product. In some embodiments, the compositioncomprises between 1 and 5 wt. % of the oxidation product. In someembodiments, the composition comprises between 0.1 and 4 wt. % of theoxidation product. In some embodiments, the composition comprisesbetween 0.5 and 4 wt. % of the oxidation product. In some embodiments,the composition comprises between 1 and 4 wt. % of the oxidationproduct. In some embodiments, the composition comprises between 0.1 and3 wt. % of the oxidation product. In some embodiments, the compositioncomprises between 0.5 and 3 wt. % of the oxidation product. In someembodiments, the composition comprises between 1 and 3 wt. % of theoxidation product. In some embodiments, the composition comprisesbetween 0.1 and 2.5 wt. % of the oxidation product. In some embodiments,the composition comprises between 0.5 and 2.5 wt. % of the oxidationproduct. In some embodiments, the composition comprises between 1 and2.5 wt. % of the oxidation product. In some embodiments, the compositioncomprises between 0.1 and 2 wt. % of the oxidation product. In someembodiments, the composition comprises between 0.5 and 2 wt. % of theoxidation product. In some embodiments, the composition comprisesbetween 1 and 2 wt. % of the oxidation product. In some embodiments, thecomposition comprises between 0.1 and 1.5 wt. % of the oxidationproduct. In some embodiments, the composition comprises between 0.5 and1.5 wt. % of the oxidation product. In some embodiments, the compositioncomprises between 0.1 and 1 wt. % of the oxidation product. In someembodiments, the composition comprises between 0.5 and 1 wt. % of theoxidation product.

In some embodiments, the composition comprises linaclotide and anacetylation product, e.g., an acetylation product comprising or having astructure of:

The composition can contain any desired concentration of the acetylationproduct. In some embodiments, the composition comprises less than 10 wt.% of the acetylation product. In some embodiments, the compositioncomprises less than 7 wt. % of the acetylation product. In someembodiments, the composition comprises less than 6 wt. % of theacetylation product. In some embodiments, the composition comprises lessthan 5 wt. % of the acetylation product. In some embodiments, thecomposition comprises less than 4 wt. % of the acetylation product. Insome embodiments, the composition comprises less than 3 wt. % of theacetylation product. In some embodiments, the composition comprises lessthan 2 wt. % of the acetylation product. In some embodiments, thecomposition comprises less than 1 wt. % of the acetylation product. Insome embodiments, the composition comprises between 0.01 and 10 wt. % ofthe acetylation product. In some embodiments, the composition comprisesbetween 0.1 and 7 wt. % of the acetylation product. In some embodiments,the composition comprises between 0.1 and 5 wt. % of the acetylationproduct. In some embodiments, the composition comprises between 0.5 and5 wt. % of the acetylation product. In some embodiments, the compositioncomprises between 1 and 5 wt. % of the acetylation product. In someembodiments, the composition comprises between 0.1 and 4 wt. % of theacetylation product. In some embodiments, the composition comprisesbetween 0.5 and 4 wt. % of the acetylation product. In some embodiments,the composition comprises between 1 and 4 wt. % of the acetylationproduct. In some embodiments, the composition comprises between 0.1 and3 wt. % of the acetylation product. In some embodiments, the compositioncomprises between 0.5 and 3 wt. % of the acetylation product. In someembodiments, the composition comprises between 1 and 3 wt. % of theacetylation product. In some embodiments, the composition comprisesbetween 0.1 and 2.5 wt. % of the acetylation product. In someembodiments, the composition comprises between 0.5 and 2.5 wt. % of theacetylation product. In some embodiments, the composition comprisesbetween 1 and 2.5 wt. % of the acetylation product. In some embodiments,the composition comprises between 0.1 and 2 wt. % of the acetylationproduct. In some embodiments, the composition comprises between 0.5 and2 wt. % of the acetylation product. In some embodiments, the compositioncomprises between 1 and 2 wt. % of the acetylation product. In someembodiments, the composition comprises between 0.1 and 1.5 wt. % of theacetylation product. In some embodiments, the composition comprisesbetween 0.5 and 1.5 wt. % of the acetylation product. In someembodiments, the composition comprises between 0.1 and 1 wt. % of theacetylation product. In some embodiments, the composition comprisesbetween 0.5 and 1 wt. % of the acetylation product.

In some embodiments, the composition comprises linaclotide and anydesired concentration of multimers. In some embodiments, the compositioncomprises less than 10 wt. % of multimer(s). In some embodiments, thecomposition comprises less than 7 wt. % of multimer(s). In someembodiments, the composition comprises less than 6 wt. % of multimer(s).In some embodiments, the composition comprises less than 5 wt. % ofmultimer(s). In some embodiments, the composition comprises less than 4wt. % of multimer(s). In some embodiments, the composition comprisesless than 3 wt. % of multimer(s). In some embodiments, the compositioncomprises less than 2 wt. % of multimer(s). In some embodiments, thecomposition comprises less than 1 wt. % of multimer(s). In someembodiments, the composition comprises between 0.01 and 10 wt. % ofmultimer(s). In some embodiments, the composition comprises between 0.1and 7 wt. % of multimer(s). In some embodiments, the compositioncomprises between 0.1 and 5 wt. % of multimer(s). In some embodiments,the composition comprises between 0.5 and 5 wt. % of multimer(s). Insome embodiments, the composition comprises between 1 and 5 wt. % ofmultimer(s). In some embodiments, the composition comprises between 0.1and 4 wt. % of multimer(s). In some embodiments, the compositioncomprises between 0.5 and 4 wt. % of multimer(s). In some embodiments,the composition comprises between 1 and 4 wt. % of multimer(s). In someembodiments, the composition comprises between 0.1 and 3 wt. % ofmultimer(s). In some embodiments, the composition comprises between 0.5and 3 wt. % of multimer(s). In some embodiments, the compositioncomprises between 1 and 3 wt. % of multimer(s). In some embodiments, thecomposition comprises between 0.1 and 2.5 wt. % of multimer(s). In someembodiments, the composition comprises between 0.5 and 2.5 wt. % ofmultimer(s). In some embodiments, the composition comprises between 1and 2.5 wt. % of multimer(s). In some embodiments, the compositioncomprises between 0.1 and 2 wt. % of multimer(s). In some embodiments,the composition comprises between 0.5 and 2 wt. % of multimer(s). Insome embodiments, the composition comprises between 1 and 2 wt. % ofmultimer(s). In some embodiments, the composition comprises between 0.1and 1.5 wt. % of multimer(s). In some embodiments, the compositioncomprises between 0.5 and 1.5 wt. % of multimer(s). In some embodiments,the composition comprises between 0.1 and 1 wt. % of multimer(s). Insome embodiments, the composition comprises between 0.5 and 1 wt. % ofmultimer(s).

In some embodiments, the composition comprises an effective amount oflinaclotide and any desired amount of reduced form linaclotide. As usedherein, the term “reduced form linaclotide” refers to linaclotide havingno disulfide bonds between cysteine amino acids. In some embodiments,the composition comprises less than 10 wt. % of reduced formlinaclotide. In some embodiments, the composition comprises less than 7wt. % of reduced form linaclotide. In some embodiments, the compositioncomprises less than 6 wt. % of reduced form linaclotide. In someembodiments, the composition comprises less than 5 wt. % of reduced formlinaclotide. In some embodiments, the composition comprises less than 4wt. % of reduced form linaclotide. In some embodiments, the compositioncomprises less than 3 wt. % of reduced form linaclotide. In someembodiments, the composition comprises less than 2 wt. % of reduced formlinaclotide. In some embodiments, the composition comprises less than 1wt. % of reduced form linaclotide. In some embodiments, the compositioncomprises between 0.01 and 10 wt. % of reduced form linaclotide. In someembodiments, the composition comprises between 0.1 and 7 wt. % ofreduced form linaclotide. In some embodiments, the composition comprisesbetween 0.1 and 5 wt. % of reduced form linaclotide. In someembodiments, the composition comprises between 0.5 and 5 wt. % ofreduced form linaclotide. In some embodiments, the composition comprisesbetween 1 and 5 wt. % of reduced form linaclotide. In some embodiments,the composition comprises between 0.1 and 4 wt. % of reduced formlinaclotide. In some embodiments, the composition comprises between 0.5and 4 wt. % of reduced form linaclotide. In some embodiments, thecomposition comprises between 1 and 4 wt. % of reduced form linaclotide.In some embodiments, the composition comprises between 0.1 and 3 wt. %of reduced form linaclotide. In some embodiments, the compositioncomprises between 0.5 and 3 wt. % of reduced form linaclotide. In someembodiments, the composition comprises between 1 and 3 wt. % of reducedform linaclotide. In some embodiments, the composition comprises between0.1 and 2.5 wt. % of reduced form linaclotide. In some embodiments, thecomposition comprises between 0.5 and 2.5 wt. % of reduced formlinaclotide. In some embodiments, the composition comprises between 1and 2.5 wt. % of reduced form linaclotide. In some embodiments, thecomposition comprises between 0.1 and 2 wt. % of reduced formlinaclotide. In some embodiments, the composition comprises between 0.5and 2 wt. % of reduced form linaclotide. In some embodiments, thecomposition comprises between 1 and 2 wt. % of reduced form linaclotide.In some embodiments, the composition comprises between 0.1 and 1.5 wt. %of reduced form linaclotide. In some embodiments, the compositioncomprises between 0.5 and 1.5 wt. % of reduced form linaclotide. In someembodiments, the composition comprises between 0.1 and 1 wt. % ofreduced form linaclotide. In some embodiments, the composition comprisesbetween 0.5 and 1 wt. % of reduced form linaclotide.

In some embodiments, the composition comprises an effective amount oflinaclotide and any desired amount of scrambled-form linaclotide. Asused herein, the term “scrambled-form linaclotide” refers to linaclotidehaving disulfide bonds between Cys₁ and Cys₁₀, between Cys₁ and Cys₁₃,between Cys₁ and Cys₅, between Cys₁ and Cys₂, between Cys₂ and Cys₆,between Cys₂ and Cys₁₃, between Cys₂ and Cys₅, between Cys₅ and Cys₆,and/or between Cys₅ and Cys₁₀. In some embodiments, the compositioncomprises less than 10 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises less than 7 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises less than 6 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises less than 5 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises less than 4 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises less than 3 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises less than 2 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises less than 1 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 0.01 and 10 wt. % of scrambled-form linaclotide. Insome embodiments, the composition comprises between 0.1 and 7 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 0.1 and 5 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises between 0.5 and 5 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 1 and 5 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises between 0.1 and 4 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 0.5 and 4 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises between 1 and 4 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 0.1 and 3 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises between 0.5 and 3 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 1 and 3 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises between 0.1 and 2.5 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 0.5 and 2.5 wt. % of scrambled-form linaclotide. Insome embodiments, the composition comprises between 1 and 2.5 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 0.1 and 2 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises between 0.5 and 2 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 1 and 2 wt. % of scrambled-form linaclotide. In someembodiments, the composition comprises between 0.1 and 1.5 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 0.5 and 1.5 wt. % of scrambled-form linaclotide. Insome embodiments, the composition comprises between 0.1 and 1 wt. % ofscrambled-form linaclotide. In some embodiments, the compositioncomprises between 0.5 and 1 wt. % of scrambled-form linaclotide.

In some embodiments, the composition comprises a total degradantconcentration of less than about 10 wt. %. In some embodiments, thecomposition comprises a total degradant concentration of less than about8 wt. %. In some embodiments, the composition comprises a totaldegradant concentration of less than about 7 wt. %. In some embodiments,the composition comprises a total degradant concentration of less thanabout 6.5 wt. %. In some embodiments, the composition comprises a totaldegradant concentration of less than about 6 wt. %. In some embodiments,the composition comprises a total degradant concentration of less thanabout 5.5 wt. %. In some embodiments, the composition comprises a totaldegradant concentration of less than about 5 wt. %. In some embodiments,the composition comprises a total degradant concentration of less thanabout 4 wt. %. In some embodiments, the composition comprises a totaldegradant concentration of less than about 3 wt. %. In some embodiments,the composition comprises a total degradant concentration of less thanabout 2.5 wt. %. In some embodiments, the composition comprises a totaldegradant concentration of less than about 2 wt. %. In some embodiments,the composition comprises a total degradant concentration of less thanabout 1 wt. %.

The pharmaceutical composition can be used to treat and diseases,disorders and conditions that are responsive to treatment with agonistsof the GC-C receptor. For example, the composition can be used to treatgastrointestinal disorders including, but not limited to, irritablebowel syndrome, constipation-predominant irritable bowel syndrome,dyspepsia (including functional dyspepsia or non-ulcer dyspepsia),gastrointestinal motility disorders, functional gastrointestinaldisorders, gastroesophageal reflux disease (GERD), Crohn's disease,ulcerative colitis, inflammatory bowel disease, functional heartburn,gastroparesis, chronic intestinal pseudo-obstruction (or colonicpseudo-obstruction), and disorders and conditions associated withconstipation, for example, chronic constipation, opioid inducedconstipation, post-surgical constipation (post-operative ileus),constipation associated with neuropathic disorders or a combination ofsymptoms thereof (such as a combination of irritable bowel syndrome andchronic constipation), or inflammation or pain associated therewith. Insome embodiments, a method is provided for treating gastrointestinaldisorders in a patient (e.g., mammal or human) diagnosed with one ormore gastrointestinal disorders or conditions, wherein the methodcomprises administering an effective amount of the composition to thepatient.

In another embodiment, a method is provided for increasing intestinalmotility in a patient in need thereof, comprising administering aneffective amount of the composition to the patient. Intestinal motilityinvolves spontaneous coordinated dissentions and contractions of thestomach, intestines, colon and rectum to move food through thegastrointestinal tract during the digestive process.

In some embodiments, the methods may comprise administering atherapeutically effective amount of the pharmaceutical composition to apatient in need thereof.

An effective amount of a composition comprising linaclotide or apharmaceutically acceptable salt thereof required to achieve desiredresults (such as desired treatment and/or symptom relief) of a subjectis dependent on several understood factors, such as the identity andseverity of the disorder being treated, as well as the age, weight,etc., of the patient being treated.

A subject or patient in whom administration of the pharmaceuticalcomposition is an effective therapeutic regimen for a disease ordisorder is preferably a human, but can be any animal, including alaboratory animal in the context of a clinical trial or screening oractivity experiment. Thus, as can be readily appreciated by one ofordinary skill in the art, the methods, compounds and compositionsdescribed herein are particularly suited for administration to anyanimal, particularly a mammal, and including, but by no means limitedto, humans, rodents and non-rodents, such as feline or canine subjects,farm animals, such as but not limited to bovine, equine, caprine, ovine,and porcine subjects, wild animals (whether in the wild or in azoological garden), research animals, such as mice, rats, rabbits,goats, sheep, pigs, dogs, cats, etc., avian species, such as chickens,turkeys, songbirds, etc., e.g., for veterinary medical use.

In some embodiments, the effective dose range of linaclotide for adulthumans is from 25 μg to 6 mg per day orally. In some embodiments, thedose range is 25 μg to 2 mg per day orally. In some embodiments, thedose range for adult humans is 50 μg to 1 mg per day orally (e.g., 50μg, 100 μg, 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950μg or 1 mg). In some embodiments, the dose range is 100 μg to 600 μg perday orally. In some embodiments, the dose is 50 μg, 100 μg, 150 μg, 200μg, 300 μg, 400 μg, 500 μg or 600 μg linaclotide per day orally. In someembodiments, the dose is 50 μg linaclotide per day orally. In someembodiments, the dose is 100 μg linaclotide per day orally. In someembodiments, the dose is 150 μg linaclotide per day orally. In someembodiments, the dose is 200 μg linaclotide per day orally. In someembodiments, the dose is 300 μg linaclotide per day orally. In someembodiments, the dose is 400 μg linaclotide per day orally. In someembodiments, the dose is 500 μg linaclotide per day orally. In someembodiments, the dose is 600 μg linaclotide per day orally.

In some embodiments, the effective pediatric dose range of linaclotideis from 0.05 μg to 2 mg per day orally. In some embodiments, theeffective pediatric dose range of linaclotide is from 0.05 μg to 100 μgper day orally. In some embodiments, the effective pediatric dose rangeof linaclotide is from 0.1 μg to 90 μg per day orally. In someembodiments, the effective pediatric dose range of linaclotide is from0.1 μg to 50 μg per day orally. In some embodiments, the effectivepediatric dose range of linaclotide is from 0.1 μg to 25 μg per dayorally. In some embodiments, the effective pediatric dose range oflinaclotide is from 0.1 μg to 10 μg per day orally. In some embodiments,the effective pediatric dose range of linaclotide is from 0.1 μg to 5 μgper day orally. In some embodiments, the effective pediatric dose rangeof linaclotide is from 0.1 μg to 1 μg per day orally. In someembodiments, the effective pediatric dose range of linaclotide is from0.1 μg to 0.5 μg per day orally. In some embodiments, the effectivepediatric dose range of linaclotide is 0.1 μg per day orally. In someembodiments, the effective pediatric dose range of linaclotide is 0.15μg per day orally. In some embodiments, the effective pediatric doserange of linaclotide is 0.25 μg per day orally. In some embodiments, theeffective pediatric dose range of linaclotide is 0.5 μg per day orally.In some embodiments, the effective pediatric dose range of linaclotideis 3.5 μg per day orally. In some embodiments, the effective pediatricdose range of linaclotide is 15 μg per day orally. In some embodiments,the effective pediatric dose range of linaclotide is 45 μg per dayorally. In some embodiments, the effective pediatric dose range oflinaclotide is 60 μg per day orally. In some embodiments, the effectivepediatric dose range of linaclotide is 90 μg per day orally.

In some embodiments, the unit dosage form and daily dose are equivalent.In some embodiments, the unit dosage form is administered with food atanytime of the day, without food at anytime of the day, with food afteran overnight fast (e.g., with breakfast). In some embodiments, the unitdosage form is administered once a day, twice a day or three times aday. In some embodiments, one, two or three unit dosage forms willcontain the daily oral dose of linaclotide. The precise amount ofcompound administered to a patient will be the responsibility of theattendant physician. However, the dose employed will depend on a numberof factors, including the age and sex of the patient, the precisedisorder being treated, and its severity.

In some embodiments, the compositions are administered as a monotherapy.In some embodiments, the composition consists essentially of aneffective amount of linaclotide. In some embodiments, the compositionconsists of an effective amount of linaclotide.

In some embodiments, the compositions are directly administered to apatient, for example, in the form of a capsule, tablet ororally-disintegrating composition (e.g., orally-disintegrating tablet orfilm). In some embodiments, the compositions are dissolved,disintegrated and/or mixed on or within food or beverage prior toadministration to patients (e.g., elderly or pediatric patients). Insome embodiments, the composition is dissolved or disintegrated in aliquid, solution, or fluid optionally containing stabilizing agent(s),preservative(s), sweetener(s), or the like, etc. prior to administrationto a patient (e.g., elderly or pediatric patient).

In some embodiments, the composition is a multiple dose composition,i.e., containing two, three, five, seven, ten, fifteen, twenty,twenty-five, thirty, forty, fifty, sixty, seventy, eighty, ninety ormore daily doses of linaclotide. In some embodiments, one or moreorally-disintegrating tablets or films containing 3.5 μg of linaclotideare dissolved or disintegrated within a liquid, solution or fluid toprovide a composition that contains a five day supply of 0.5 μg oflinaclotide dosages of the composition (“a five dose composition”). Insome embodiments, one or more orally-disintegrating tablets or filmscontaining 15 μg of linaclotide are dissolved or disintegrated within aliquid, solution, or fluid to provide a composition that contains athirty day supply of 0.5 μg of linaclotide dosages of the composition(“a thirty dose composition”). In some embodiments, one or moreorally-disintegrating tablets or films containing 45 μg of linaclotideare dissolved or disintegrated within a liquid, solution, or fluid toprovide a composition that contains a ninety day supply of 0.5 μg oflinaclotide dosages of the composition (“a ninety dose composition”). Insome embodiments, one or more orally-disintegrating tablets or filmscontaining 60 μg of linaclotide are dissolved or disintegrated within aliquid, solution, or fluid to provide a composition that contains a 120day supply of 0.5 μg of linaclotide dosages of the composition (“a 120dose composition”). In some embodiments, one or moreorally-disintegrating tablets or films containing 90 μg of linaclotideare dissolved or disintegrated within a liquid, solution, or fluid toprovide a composition that contains a 180 day supply of 0.5 μg oflinaclotide dosages of the composition (“a 180 dose composition”).

In other embodiments, the compositions are administered as part of acombination therapy. For example, a composition may be used incombination with other drugs or therapies that are used in thetreatment, prevention, suppression, and/or amelioration of the diseasesor conditions for which compounds of the invention are useful. Thelinaclotide can be co-administered or co-formulated with othermedications. In one embodiment, the linaclotide composition can beco-administered with other medications used to treat gastrointestinaldisorders including but not limited to acid suppressing agents such asHistamine-2 receptor agonists (H2As) and/or proton pump inhibitors(PPIs).

Such other drug(s) may be administered, by a route and in an amountcommonly used therefore, contemporaneously or sequentially with acompound of the invention. When a compound of the present invention isused contemporaneously with one or more other drugs, a pharmaceuticalunit dosage form containing such other drugs in addition to the compoundof the invention may be employed. Accordingly, the pharmaceuticalcompositions of the present invention include those that also containone or more other active components, in addition to a compound ofinvention.

Several methods can be used for evaluating the bioactivity of thelinaclotide composition, including, but not limited to, immunoassays(e.g., enzyme-linked immunosorbent assay), radioimmuno assays,immunoradiometric assays, gel electrophoresis (e.g., SDS-PAGE), highperformance liquid chromatography (HPLC), and/or high performancecapillary electrophoresis (HPCE). In some embodiments, the bioactivityof the composition is assessed by a method comprising fixinglinaclotide, incubating linaclotide with guanylate cyclase C (GCC),incubating GCC bound linaclotide with antibodies against GCC, incubatingGCC antibody-bound linaclotide with fluorescently labeled antibodiesagainst GCC antibodies, and detecting the linaclotide bound to the GCCantibodies by measuring the fluorescence intensity using a plate reader.The drug concentration can then be calculated based on the fluorescencereading of the solution.

For example, the bioactivity of the linaclotide compositions can beassessed and quantified using the following method, although othermethods are available. The composition is added to a volumetric flaskcontaining 60 ml of phosphate buffer having a pH of 4.5, and the flaskis shaken for 60 minutes. 0.2 ml of the supernatant is then removed, andis added into one or more wells of a 96-well plate that is coated withGCC. The plate is sealed and incubated at 37° C. for 2 hr. At the end ofincubation, the sample is removed and the plate is washed with phosphatebuffered saline (PBS). The bound linaclotide is then incubated for 1hour, at room temperature, with GCC (such as is available fromSigma-Aldrich Inc.) labeled with fluorescein isocyanate (FITC) inblocking buffer. After incubation, the well is washed with PBS. Thefluorescence intensity of the end product is detected, for example, byusing a plate reader. The linaclotide concentration is then calculatedbased on the fluorescence reading of the solution.

Definitions

Linaclotide is a peptide that consists of the amino acid sequence Cys₁Cys₂ Glu₃ Tyr₄ Cys₅ Cys₆ Asn₇ Pro₈ Ala₉ Cys₁₀ Thr₁ Gly₁₂ Cys₁₃ Tyr₁₄.Linaclotide can exist in free form or in the form of a pharmaceuticallyacceptable salt or hydrate.

As used herein, unless otherwise indicated, the term “entry into a useenvironment” means contact of the composition with saliva of the patientto whom it is administered, or with a fluid intended to simulate saliva,e.g., having a pH greater than 5, or with a phosphate buffer solutionhaving a pH of 4.5 and maintained at 37±1° C.

The term “released from”, when referring to the release of linaclotidefrom the composition, unless otherwise indicated, is used herein to meanthat the linaclotide no longer remains in a composition form.

As used herein, unless otherwise indicated, “stabilizing agent” refersto a polymer, sterically hindered primary amine (e.g., amino acid), orcation (e.g., metal cation) component of the composition which isincluded in the composition in a stabilizing amount. For example, apolymeric stabilizing agent is a polymer that is included in thecomposition in a stabilizing amount. Similarly, a sterically hinderedprimary amine stabilizing agent is a sterically hindered primary aminethat is included in the composition in a stabilizing amount. Moreover, acationic stabilizing agent is a cation that is included in thecomposition in a stabilizing amount.

As used herein, unless otherwise indicated, “stabilizing amount” refersto a concentration, within the composition, of a polymer, stericallyhindered primary amine (e.g., amino acid), or metal cation component atwhich the component increases the stability of linaclotide in thecomposition, as compared to a similar composition not having astabilizing amount of the same component.

As used herein, unless otherwise indicated, a “low-dose pharmaceuticalcomposition” is a pharmaceutical composition that comprises less than125 μg of linaclotide, for example less than 110 μg, less than 100 μg,less than 80 gig, less than 70 μg, less than 60 μg, or even less than 50μg of linaclotide (for example, between 0.001 μg and 125 μg, between0.001 μg and 100 μg, between 0.001 μg and 80 μg, or between 0.001 μg and50 μg of linaclotide).

As used herein, unless otherwise indicated, the term “substantially all”means at least about 90%, for example, at least about 95% or even atleast about 99%.

As used herein, unless otherwise indicated, the term “isolated andpurified” means at least 95 percent pure (for example, at least 96%pure, at least 97% pure, at least 98% pure, or even at least 99% pure),as measured, for example, by chromatographic purity using HPLC.

As used herein, unless otherwise indicated, “therapeutically effectiveamount” means the amount of a linaclotide or a pharmaceuticallyacceptable salt thereof that, when administered to a mammal for treatinga state, disorder or condition, is sufficient to effect a treatment (asdefined below). The “therapeutically effective amount” will varydepending on the compound, the disease and its severity and the age,sex, weight, physical condition and responsiveness of the mammal to betreated. For example, a therapeutically effective amount of linaclotide,or its pharmaceutically acceptable salt or hydrate, can be an amounteffective to treat gastrointestinal disorders, including irritable bowelsyndrome, constipation-predominant irritable bowel syndrome, chronicconstipation, opioid induced constipation and/or dyspepsia.

As used herein, unless other indicated, “pharmaceutically acceptable”means biologically or pharmacologically compatible for in vivo use inanimals or humans, and preferably means, approved by a regulatory agencyof the Federal or a state government or listed in the U.S. Pharmacopeiaor other generally recognized pharmacopeia for use in animals, and moreparticularly in humans.

As used herein, unless otherwise indicated, the term “treat”, in all itsverb forms, is used herein to mean to relieve, alleviate, prevent,and/or manage at least one symptom of a disorder in a subject, thedisorder including, for example, a gastrointestinal disorder, such as,irritable bowel syndrome, constipation-predominant irritable bowelsyndrome, chronic constipation, opioid induced constipation, dyspepsia,or a combination of symptoms thereof. Within the meaning of the presentinvention, the term “treat” also denotes, to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/orreduce the risk of developing or worsening a disease. The term“treatment” means the act of “treating” as defined above.

As used herein, unless otherwise indicated, the term “additives” refersto a pharmaceutically acceptable additive. Pharmaceutically acceptableadditives include, without limitation, binders, disintegrants,dispersing additives, lubricants, glidants, antioxidants, coatingadditives, diluents, surfactants, flavoring additives, humectants,absorption promoting additives, controlled release additives,anti-caking additives, anti-microbial agents (e.g., preservatives),colorants, desiccants, plasticizers and dyes.

As used herein, unless otherwise indicated, an “excipient” is anypharmaceutically acceptable additive, filler, binder or agent.

As used herein, unless otherwise indication, “stressed conditions” referto 40° C. and 75% relative humidity (RH).

As used here, unless otherwise indicated, the terms “about” and“approximately” mean within an acceptable error range for the particularvalue as determined by one of ordinary skill in the art, which willdepend, in part, on how the value is measured or determined, i.e., thelimitations of the measurement system. For example, “about” can meanwithin 1 or more than 1 standard deviation, per practice in the art.Alternatively, “about” with respect to the compositions can mean plus orminus a range of up to 20%, preferably up to 10%. Alternatively,particularly with respect to biological systems or processes, the termcan mean within an order of magnitude, preferably within 5-fold, andmore preferably within 2-fold, of a value. Particular values aredescribed in the application and claims, unless otherwise stated theterm “about” means within an acceptable error range for the particularvalue.

All weight percentages (i.e., “% by weight” and “wt. %” and w/w)referenced herein, unless otherwise indicated, are measured relative tothe total weight of the pharmaceutical composition.

The term “consisting essentially of”, and variants thereof, when used torefer to the composition, are used herein to mean that the compositionincludes linaclotide and other desired pharmaceutically inactiveadditives, excipients, and/or components (e.g., polymers, stericallyhindered primary amines, cations, filling agents, binders, carriers,excipients, diluents, disintegrating additives, lubricants, solvents,dispersants, coating additives, absorption promoting additives,hydrolysis products, formaldehyde imine products, oxidation products,acetylation products, deamidation products, multimers, controlledrelease additives, anti-caking additives, anti-microbial additives,preservatives, sweetening additives, colorants, flavors, desiccants,plasticizers, dyes, or the like), and no other active pharmaceuticalingredient(s).

EXAMPLES

The following examples are merely illustrative of the present inventionand should not be construed as limiting the scope of the invention inany way as many variations and equivalents that are encompassed by thepresent invention will become apparent to those skilled in the art uponreading the present disclosure.

The following tests were employed in the examples section, unlessotherwise indicated:

1) Stability of Linaclotide Compositions.

For stability evaluation, linaclotide compositions (0.15 mg theoretical,actual 0.135 mg) were packaged into a HDPE bottle with desiccant, andstored under at 40° C. and 75% RH (“stressed conditions”). The amount oflinaclotide was assayed initially and after up to 18 months of storageat stressed conditions. The concentration of linaclotide was analyzedand quantified using an HPLC method with the following mobile phasegradient: Mobile phase A: 50 mM of sodium perchlorate in a solventcontaining 76% water and 24% acetonitrile and 0.1% of trifluoroaceticacid; Mobile phase B: 50 mM of sodium perchlorate in a solventcontaining 5% water and 95% acetonitrile and 0.1% of trifluoroaceticacid; Flow rate: 0.6 ml/min; Column: YMC Pro C18, 150 mm×3 mm ID, 3 μmor equivalent; Column temperature: 40° C.; Fluorescence detection:excitation: 274 nm; emission: 303 nm; Injection volume: 100 μl.

2) Analysis of Total Degradants in the Pharmaceutical Composition:

Degradant analysis was performed using an HPLC method employing thefollowing conditions: Mobile phase A: Water:acetonitrile 98:2, with 0.1%(v/v) of trifluoroacetic acid; Mobile phase B: Water:acetonitrile 5:95,with 0.1% (v/v) of trifluoroacetic acid; Flow rate: 0.6 ml/min; Column:YMC Pro C18, 150 mm×3 mm ID, 3 μm or equivalent; Column temperature: 40°C.; UV detection: excitation: 220 nm; Injection volume: 50 μl. Thepercentage amounts of degradants in the composition were calculated byquantifying the area of all peaks in the HPLC chromatogram to obtain the“total peak area”, and dividing the peak area of each degradant by thetotal peak area. Specific degradants assayed include, for example, thehydrolysis product, Asp-7.

Example 1

Linaclotide beads were prepared in the following manner using thecomponents set forth in Table 1. First, a linaclotide solution wasprepared by combining linaclotide, polyvinyl alcohol, calcium chloride,meglumine and water in the concentrations set forth in Table 1. Thelinaclotide solution was then pH-adjusted to about 2.5 and mixed untilclear. Next, the linaclotide solution was layered onto isomalt beads byspraying the beads with the linaclotide solution using a Wursterprocess. The linaclotide-layered beads were then dried until the productloss on drying (LOD) was less than about 3%.

TABLE 1 Linaclotide beads, 5 μg/50 mg Weight Components (g) Wt. %Linaclotide 0.24 0.012 Isomalt 1915 95.8 Meglumine 2.6 0.1 Calciumchloride dihydrate 2.0 0.1 PVA 80 4 HCl Q.S. QS Purified water* 1000 QSTOTAL 2000 100.0 *Water is removed during the manufacturing process

The stability performance of the linaclotide beads were assessedfollowing storage of the beads for 1 month at 40° C. and 75% RH in 45 ccHDPE bottles (induction sealed and not containing desiccant). Results ofthe stability performance assay are set forth in Table 2.

TABLE 2 Results of stability performance assay Asp-7 Imine TimeDegradant Degradant Purity % initial 0.11 <0.1 97.8 1 wk 0.25 0.11 96.52 wk 0.31 <0.1 96.5 1 m 0.37 <0.1 92.6

Example 2

Linaclotide beads were prepared in the following manner using thecomponents set forth in Table 3. First, a linaclotide solution wasprepared by combining linaclotide, polyvinyl alcohol, calcium chloride,histidine and water in the concentrations set forth in Table 3. Thelinaclotide solution was then pH-adjusted to about 2.5 and mixed untilclear. Next, the linaclotide solution was layered onto isomalt beads byspraying the beads with the linaclotide solution using a Wursterprocess. The linaclotide-layered beads were then dried until the productloss on drying (LOD) was less than about 3%.

TABLE 3 Linaclotide beads, 5 μg/50 mg Weight Components (g) Wt. %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Histidine 2 0.1 Calciumchloride dihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 —TOTAL 2000 100.0 *Water is removed during the manufacturing process

Example 3

Linaclotide beads were prepared in the manner described in Example 2using the components set forth in Table 4.

TABLE 4 Linaclotide beads, 5 μg/50 mg Weight Components (g) Wt. %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Leucine 2 0.1 Calcium chloridedihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 — TOTAL 2000100.0 *Water is removed during the manufacturing process

Example 4

Linaclotide beads were prepared in the manner described in Example 2using the components set forth in Table 5.

TABLE 5 Linaclotide beads, 5 μg/50 mg Weight Components (g) Wt. %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Arginine 2 0.1 Calcium chloridedihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 — TOTAL 2000100.0 *Water is removed during the manufacturing process

Example 5

Linaclotide beads were prepared in the manner described in Example 2using the components set forth in Table 6.

TABLE 6 Linaclotide beads, 5 μg/50 mg Weight Components (grams) Wt. %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Lysine 2 0.1 Calcium chloridedihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 — TOTAL 2000100.0 *Water is removed during the manufacturing process

Example 6

The stability and dissolution performance were assessed for thelinaclotide beads prepared in Examples 2-5 following storage of thebeads at 40° C. and 75% RH in HDPE bottles (sealed with heat and notcontaining desiccant). Results of the stability and dissolutionperformance assays are set forth in Tables 7-8 and FIG. 1 (whichillustrates imine degradant concentrations).

TABLE 7 Stability of linaclotide beads at 40° C., 75% RH Assay(normalized) Amino acid 1 wk 2 wk 1 mo Histidine 96.5 99.7 93.1 Leucine95.9 95.2 93.5 Lysine 92.5 91.4 87.6 Arginine 96.9 92.5 89.5

TABLE 8 Degradation profile of linaclotide beads at 40° C., 75% RHDuration of Asp-7 Imine Amino acid Storage Degradant Degradant PurityHistidine initial 0.18 0.16 98.3 1 wk 0.11 0.27 98.3 2 wk 0.15 0.41 96.51 mo 0.26 0.61 93.4 Leucine initial — 0.18 97.6 1 wk 0.17 0.79 96.9 2 wk0.19 1.00 94.8 1 mo 0.20 1.92 90.7 Lysine initial 0.17 0.24 97.5 1 wk0.12 1.74 94.8 2 wk 0.18 2.57 92.0 1 mo 0.14 3.64 85.9 Arginine initial0.10 0.14 98.9 1 wk 0.18 1.41 95.7 2 wk 0.28 2.12 92.8 1 mo 0.24 2.5588.6

Example 7

Linaclotide beads may be prepared in the manner described in Example 2using the components set forth in Table 9.

TABLE 9 Linaclotide beads, 5 μg/50 mg Components Weight (g) Wt %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Melamine 2 0.1 Calcium chloridedihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 — TOTAL 2000100.0 *Water is removed during the manufacturing process

Example 8

Linaclotide beads may be prepared in the manner described in Example 2using the components set forth in Table 10.

TABLE 10 Linaclotide beads, 5 μg/50 mg Components Weight (g) Wt %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Gelatin 2 0.1 Calcium chloridedihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 — TOTAL 2000100.0 *Water is removed during the manufacturing process

Example 9

Linaclotide beads may be prepared in the manner described in Example 2using the components set forth in Table 11.

TABLE 11 Linaclotide beads, 5 μg/50 mg Components Weight (g) Wt %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Glycine 2 0.1 Calcium chloridedihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 — TOTAL 2000100.0 *Water is removed during the manufacturing process

Example 10

Linaclotide beads may be prepared in the manner described in Example 2using the components set forth in Table 12.

TABLE 12 Linaclotide beads, 5 μg/50 mg Components Weight (g) Wt %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Glycine-Leucine 2 0.1 Calciumchloride dihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 —TOTAL 2000 100.0 *Water is removed during the manufacturing process

Example 11

Linaclotide beads may be prepared in the manner described in Example 2using the components set forth in Table 13.

TABLE 13 Linaclotide beads, 5 μg/50 mg Components Weight (g) Wt %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Leucine-Glycine 2 0.1 Calciumchloride dihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 —TOTAL 2000 100.0 *Water is removed during the manufacturing process

Example 12

Linaclotide beads may be prepared in the manner described in Example 2using the components set forth in Table 14.

TABLE 14 Linaclotide beads, 5 μg/50 mg Components Weight (g) Wt %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Albumin 2 0.1 Calcium chloridedehydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 — TOTAL 2000100.0 *Water is removed during the manufacturing process

Example 13

Linaclotide beads were prepared in the manner described in Example 2using the components set forth in Table 15.

TABLE 15 Linaclotide beads, 5 μg/50 mg Weight Components (g) Wt. %Linaclotide 0.24 0.012 Isomalt 1916 95.8 Asparagine 2 0.1 Calciumchloride dihydrate 2.0 0.1 PVA 80 4 HCl Q.S. — Purified water* 1000 —TOTAL 2000 100.0 *Water is removed during the manufacturing process

The present invention is not to be limited in scope by the specificembodiments described herein. Indeed, various modifications of theinvention in addition to those described herein will become apparent tothose skilled in the art from the foregoing description and theaccompanying FIGURES. Such modifications are intended to fall within thescope of the appended claims. It is further to be understood that allvalues are approximate, and are provided for description.

All patents, patent applications, publications, product descriptions,and protocols are cited throughout this application, the disclosures ofwhich are incorporated herein by reference in their entireties for allpurposes.

What is claimed is:
 1. A pharmaceutical composition comprising linaclotide, a cation or pharmaceutically acceptable salt thereof and an amine selected from meglumine or a mixture of meglumine and histidine.
 2. The composition of claim 1, wherein the amine is meglumine.
 3. A pharmaceutical composition comprising linaclotide, a cation or pharmaceutically acceptable salt thereof and histidine, wherein the composition has a molar ratio of cation:histidine of less than 2:1.
 4. The composition of claim 1 or claim 3, wherein the composition further comprises a polymer.
 5. The composition of claim 4, wherein the polymer is selected from polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) or a mixture thereof.
 6. A method of treating a gastrointestinal disorder comprising administering to a patient in need thereof, a therapeutically effective amount of the composition of claim 1 or claim
 3. 7. The method of claim 6, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome, chronic constipation, opioid induced constipation and dyspepsia.
 8. The method of claim 7, wherein the gastrointestinal disorder is chronic constipation.
 9. The method of claim 7, wherein the gastrointestinal disorder is constipation-predominant irritable bowel syndrome.
 10. A method of making the composition of claim 1, comprising combining linaclotide with a cation or pharmaceutically acceptable salt thereof and an amine selected from meglumine or a mixture of meglumine and histidine.
 11. A composition prepared by the method of claim
 10. 12. A method of making the composition of claim 3, comprising combining linaclotide with a cation or pharmaceutically acceptable salt thereof and histidine, wherein the composition has a molar ratio of cation:histidine of less than 2:1.
 13. A composition prepared by the method of claim
 12. 14. A pharmaceutical composition comprising linaclotide, a cation or pharmaceutically acceptable salt thereof and a dipeptide selected from glycine-leucine, leucine-glycine, or a mixture thereof.
 15. The composition of claim 14, wherein the composition further comprises a polymer.
 16. The composition of claim 15, wherein the polymer is selected from polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) or a mixture thereof.
 17. A method of treating a gastrointestinal disorder comprising administering to a patient in need thereof, a therapeutically effective amount of the composition of claim
 14. 18. The method of claim 17, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome, chronic constipation, opioid induced constipation and dyspepsia.
 19. The method of claim 18, wherein the gastrointestinal disorder is chronic constipation.
 20. The method of claim 18, wherein the gastrointestinal disorder is constipation-predominant irritable bowel syndrome.
 21. A method of making the composition of claim 14, comprising combining linaclotide with a cation or pharmaceutically acceptable salt thereof and a dipeptide selected from glycine-leucine, leucine-glycine, or a mixture thereof.
 22. A composition prepared by the method of claim
 21. 23. The composition of claim 1, wherein the composition comprises Ca²⁺ and an amino acid selected from meglumine or mixture of meglumine and histidine in a molar ratio of Ca²⁺:amino acid between about 1.3:1 and 0.7:1.
 24. The composition of claim 1, wherein the composition comprises Ca²⁺ and an amino acid selected from meglumine or mixture of meglumine and histidine in a molar ratio of Ca²⁺:amino acid between about 1.1:1 and 0.9:1.
 25. The composition of claim 3, wherein the composition comprises Ca²⁺ and histidine in a molar ratio of Ca²⁺:histidine between about 1.3:1 and 0.7:1.
 26. The composition of claim 3, wherein the composition comprises Ca²⁺ and histidine in a molar ratio of Ca²⁺:histidine between about 1.1:1 and 0.9:1. 